Van Strum & Towne Inc. Has $7.38 Million Stake in Johnson & Johnson (NYSE:JNJ)

Van Strum & Towne Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,367 shares of the company’s stock after buying an additional 550 shares during the quarter. Johnson & Johnson makes up about 3.1% of Van Strum & Towne Inc.’s investment portfolio, making the stock its 9th biggest position. Van Strum & Towne Inc.’s holdings in Johnson & Johnson were worth $7,377,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Argent Trust Co lifted its stake in shares of Johnson & Johnson by 1.4% during the third quarter. Argent Trust Co now owns 186,724 shares of the company’s stock valued at $29,082,000 after acquiring an additional 2,547 shares during the period. tru Independence LLC lifted its stake in Johnson & Johnson by 0.7% in the third quarter. tru Independence LLC now owns 26,655 shares of the company’s stock valued at $4,152,000 after buying an additional 177 shares during the period. Spinnaker Trust grew its position in shares of Johnson & Johnson by 3.7% during the 3rd quarter. Spinnaker Trust now owns 43,921 shares of the company’s stock worth $6,841,000 after buying an additional 1,553 shares during the period. NewEdge Wealth LLC increased its stake in Johnson & Johnson by 11.4% in the third quarter. NewEdge Wealth LLC now owns 92,398 shares of the company’s stock valued at $14,391,000 after purchasing an additional 9,427 shares in the last quarter. Finally, Loudon Investment Management LLC boosted its position in shares of Johnson & Johnson by 1.3% during the third quarter. Loudon Investment Management LLC now owns 6,071 shares of the company’s stock worth $946,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Stock Up 0.7 %

JNJ stock opened at $157.87 on Tuesday. The business’s 50 day simple moving average is $158.18 and its 200 day simple moving average is $158.62. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The firm has a market capitalization of $380.04 billion, a PE ratio of 11.43, a PEG ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter last year, the company posted $2.35 EPS. Johnson & Johnson’s quarterly revenue was down 9.7% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Raymond James raised their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Tuesday, February 6th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Morgan Stanley dropped their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $176.14.

Get Our Latest Stock Report on JNJ

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.